PURPOSE: To determine if histamine receptor stimulation mediates increased blood-retinal barrier (BRB) permeability in patients with diabetic retinopathy, as it does in experimental diabetes. METHODS:Fourteen patients with typeI (insulin-dependent) diabetes and mild nonproliferative diabetic retinopathy were treated with combined astemizole, 20 mg, and ranitidine, 600 mg, or an identical placebo for 6 months in a double-masked fashion. Blood-retinal barrier permeability was measured by vitreous fluorometry at baseline and at 3 and 6 months. RESULTS:Permeability was significantly reduced in the group treated with antihistamines (P < 0.05) compared with the placebo group. There were no concomitant significant changes in systemic arterial blood pressure or HbA1c values. CONCLUSION: These pilot data suggest that histamine receptors influence permeability of the BRB in human diabetes. Further studies of the effects of antihistamines on diabetic retinopathy are warranted.
RCT Entities:
PURPOSE: To determine if histamine receptor stimulation mediates increased blood-retinal barrier (BRB) permeability in patients with diabetic retinopathy, as it does in experimental diabetes. METHODS: Fourteen patients with type I (insulin-dependent) diabetes and mild nonproliferative diabetic retinopathy were treated with combined astemizole, 20 mg, and ranitidine, 600 mg, or an identical placebo for 6 months in a double-masked fashion. Blood-retinal barrier permeability was measured by vitreous fluorometry at baseline and at 3 and 6 months. RESULTS: Permeability was significantly reduced in the group treated with antihistamines (P < 0.05) compared with the placebo group. There were no concomitant significant changes in systemic arterial blood pressure or HbA1c values. CONCLUSION: These pilot data suggest that histamine receptors influence permeability of the BRB in humandiabetes. Further studies of the effects of antihistamines on diabetic retinopathy are warranted.
Authors: H J Van Schaik; B Heintz; M Larsen; E Leite; V Rosas; R Schalnus; J A Van Best Journal: Graefes Arch Clin Exp Ophthalmol Date: 1997-10 Impact factor: 3.117
Authors: M J Gastinger; A J Barber; S A Khin; C S McRill; T W Gardner; D W Marshak Journal: Invest Ophthalmol Vis Sci Date: 2001-10 Impact factor: 4.799
Authors: David G Belair; Jordan A Whisler; Jorge Valdez; Jeremy Velazquez; James A Molenda; Vernella Vickerman; Rachel Lewis; Christine Daigh; Tyler D Hansen; David A Mann; James A Thomson; Linda G Griffith; Roger D Kamm; Michael P Schwartz; William L Murphy Journal: Stem Cell Rev Rep Date: 2015-06 Impact factor: 5.739